Nitrobenzofuroxane derivatives as dual action HIV-1 inhibitors

   
Korolev S.P.1 , Pustovarova M.A.1, Starosotnikov A.M.2, Bastrakov M.A.2, Agapkina Yu.Yu.1, Shevelev S.A.2, Gottikh M.B.1

1. Belozeksky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia
2. Zelinsky Institute of Organic Chemistry, Moscow, Russia
Section: Short Communication
DOI: 10.18097/PBMC20166206725      UDK: 547.854"4.057      PubMed Id: 28026819
Year: 2016  Volume: 62  Issue: 6  Pages: 725-728
Human immunodeficiency virus first type (HIV-1) is a main cause of one of the most dangerous diseases, AIDS. The search for new inhibitors of the virus still remains an urgent task. One approach to suppress the HIV infection is to use a double-acting inhibitors, i.e. inhibitors directed to two stages of the viral life cycle. The catalytic domain of HIV-1 integrase has a similar spatial organization with ribonuclease (RNase H) domain of HIV-1 reverse transcriptase, and approach aimed to create HIV-1 integrase and RNase H double-acting is very promising. In this work we synthesized a series of 6-nitrobenzofuroxane derivatives and studied their ability to inhibit two viral enzymes – integrase and RNase H HIV-1.
Download PDF:
Reference:

Korolev S.P., Pustovarova M.A., Starosotnikov A.M., Bastrakov M.A., Agapkina Yu.Yu., Shevelev S.A., Gottikh M.B. (2016) Biomeditsinskaya khimiya, 62(6), 725-728.
This paper is also available as the English translation:10.1134/S1990750817030064
References  
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)
        

© Institute of Biomedical Chemistry, Moscow, Russia